Clinical Trials for Food Allergies: New Treatment Options Recruiting Now

For millions of Americans living with food allergies, daily life involves constant vigilance—reading every label, asking about ingredients at restaurants, and carrying epinephrine auto-injectors everywhere. While avoidance and emergency treatment remain the standard of care, clinical trials are exploring new therapies that could fundamentally change how food allergies are managed.

The Current Food Allergy Landscape

Food allergies affect approximately 32 million Americans, including 5.6 million children under age 18. The most common allergens—peanut, tree nuts, milk, egg, wheat, soy, fish, and shellfish—account for 90% of all reactions. For many, the burden goes beyond physical risk; it impacts quality of life, mental health, and social participation.

Standard management has long been strict avoidance plus emergency epinephrine. But the treatment landscape is shifting.

Emerging Therapies in Clinical Trials

1. Omalizumab (Anti-IgE Therapy) — Weight-Based Dosing

A Phase 2 trial (NCT06943534) led by Massachusetts General Hospital is investigating omalizumab (Xolair) at weight-based doses for multiple food allergies. Unlike the current FDA-approved dosing for asthma and chronic hives, this study tests higher doses (5mg/kg and 15mg/kg) regardless of IgE level—potentially expanding eligibility to patients previously excluded due to very high allergic antibody levels.

Key details:

• Locations: Boston (Mass General), Chapel Hill (UNC), Dallas (UT Southwestern)
• Age range: 1–55 years
• Conditions: Peanut, cashew, walnut, egg, or milk allergy
• Design: Weight-based dosing, not limited by IgE level

2. Oral Immunotherapy (OIT) Variants

Multiple trials are testing refined OIT protocols—gradually increasing doses of the allergen under medical supervision to build tolerance. Newer approaches combine OIT with biologics (like omalizumab or dupilumab) to improve safety and accelerate desensitization.

3. Epicutaneous Immunotherapy (EPIT)

Patch-based delivery systems (like the Viaskin Peanut patch) deliver allergen through the skin, offering a non-oral route that may reduce systemic reactions. Several Phase 3 trials are ongoing or recently completed.

4. Microbiome-Targeted Therapies

Emerging research links gut microbiome composition to food allergy development. Trials are investigating whether specific probiotic formulations or fecal microbiota transplantation can prevent or treat food allergies by modulating immune response.

How to Find a Food Allergy Trial Near You

Finding the right trial requires matching your specific allergy, age, location, and medical history to actively recruiting studies. Corterve's matching platform simplifies this by:

1. Search by condition — Filter for "food allergy," "peanut allergy," "milk allergy," etc.
2. Location-aware results — See trials recruiting at centers near your ZIP code
3. Eligibility pre-screen — Answer a few structured questions (age, diagnosis, travel willingness) to gauge potential fit
4. Direct referral — If you pre-qualify, we connect you with the study team for formal screening

> Important: Pre-qualification is not a guarantee of eligibility. The research site makes the final determination after full medical review. Always discuss trial participation with your allergist/immunologist.

Questions to Ask Before Enrolling

• What is the study's primary goal (safety, efficacy, dosing)?
• What are the time commitments (visits, duration, travel)?
• What are the known risks and side effects?
• Will I need to stop current medications?
• Is there a placebo arm, and what happens after the trial ends?
• What costs are covered by the sponsor?

Take the Next Step

Search actively recruiting food allergy trials now: Corterve Food Allergy Trials

Get alerts for new trials matching your profile: Register your email and ZIP code to be notified when new studies open near you.

Disclaimer: Corterve is a clinical trial matching platform, not a medical provider. We do not give medical advice, diagnose conditions, or guarantee trial eligibility. All eligibility determinations are made by the study's research team. Consult your healthcare provider before making any changes to your allergy management plan.